Caris Life Sciences Launches Caris Target Now™ Select for NSCLC, Melanoma, and Cancers of the Breast, Colon, and Ovary

Informations

• Publié par: jfk-communications-inc
• Nombre de lectures: 6
• Langue: English

Extrait

Caris Life Sciences Launches Caris Target

Now™ Select for NSCLC, Melanoma, and

Cancers of the Breast, Colon, and Ovary

PR Newswire

IRVING, Texas, June 26, 2012

- Enhanced Molecular Profiling Service Now Includes More Biomarker

Analysis Options, Faster Turnaround Time, and Clinical Trial Matching

IRVING, Texas

,

June 26, 2012

/PRNewswire/

--

Caris Life Sciences®, a leading

biosciences company focused on enabling precise and personalized healthcare

through molecular profiling and blood-based diagnostic services, today

announced the launch of Caris Target Now™

Select

, an advanced, evidence-

based molecular profiling service for patients with non-small cell lung cancer

(NSCLC), melanoma, and cancers of the breast, colon and ovary. In addition,

the company has enhanced the original Caris Target Now comprehensive

molecular profiling service offering for all solid tumors.

"This latest effort by Caris is another significant step in what I call health

improvement, while at the same time fulfilling on the promise of personalized

medicine," said David D. Halbert, Chairman and CEO, Caris Life Sciences. "With

these enhancements, we believe we can prolong the lives of patients and

improve outcomes, while also lowering costs to the healthcare system."

Caris Target Now

Select

incorporates updated, evidence-based technology

platforms to determine the genomic information unique to a patient's tumor

based on the presence of relevant biomarkers. In addition to providing focused

biomarker profiles designed for earlier-stage cancer patients, it offers the

advantages of known "on-Compendium-only" drug associations, faster

turnaround time, the capability to derive meaningful results from smaller tissue

samples, up to 30 reported biomarkers per patient (depending on tumor type),

and – for the first time –

Clinical Trials Connector

™, a service that enables

biomarker-specific clinical trial matching.

"Caris Target Now

Select

is an important new tool to assist physicians in

choosing among standard drug choices earlier in the course of treatment,

where molecular profiling can have the largest benefit to patient care," said

Tom Spalding, Oncology Senior Vice President and Group Head, Caris Life

Sciences. "In addition, the new Clinical Trials Connector uncovers even more

possibilities by linking patients to open and enrolling clinical trials based upon

their individual biomarker status."

Using the strongest clinical evidence, Caris Target Now

Select

highlights known

therapeutic associations with appropriate, tumor-specific treatments for the

five target tumor types, as identified in the National Comprehensive Cancer

Network Drug & Biologics Compendium™[1]. In addition, the newly enhanced

version of Caris' original molecular profiling service (now renamed Caris Target

Now

Comprehensive

) provides both on- and off-Compendium therapeutic

associations for all solid tumors, across a wide range of evidence.

"Caris Target Now

Select

is an evidence-based molecular profiling service that

can help both earlier-stage and later-stage cancer patients, as it employs the

most relevant biomarkers and technologies to help decode a patient's tumor,"

said Sandeep Reddy, MD, Clinical Professor of Medicine at the David Geffen

School of Medicine at the University of California, Los Angeles (UCLA) and

Senior Medical Director at Caris. "This service allows physicians to augment

their years of experience with advanced theranostic resources, further

personalizing cancer care based on the expression status of specific

biomarkers."

Through analysis with multiple, highly integrated technology platforms such as

immunohistochemistry (IHC), fluorescence

in situ

hybridization (FISH),

polymerase chain reaction (PCR), and DNA sequencing, both the Caris Target

Now

Select

and

Comprehensive

services provide vital information that may be

useful to oncologists in individualizing therapeutic regimens for cancer patients.

By utilizing the most relevant, evidence-based molecular profiling technologies

to determine the biomarkers unique to a patient's tumor, and performing an

extensive review of clinical literature correlating biomarkers to drug response,

Caris Target Now

Select

can help illuminate the benefit (or lack thereof) of

specific agents, and may reveal appropriate treatments not previously

considered.

Both services can be requested for cancer patients by physicians seeking to

utilize biomarker analysis to inform therapeutic decision-making. For more

information, visit www.caristargetnow.com.

About Caris Life Sciences

Caris Life Sciences is a leading biosciences company focused on developing and

delivering innovative molecular diagnostic, prognostic, and theranostic services.

The company's evidence-based molecular profiling service, Caris Target Now™,

matches molecular data generated from a patient's tumor with biomarker/drug

associations derived from the world's leading clinical cancer literature. Caris

Target Now uses the most advanced and clinically relevant technologies to

provide physicians with information to aid in the selection of personalized

cancer treatments more likely to work for each patient. Caris is also developing

a series of blood tests based on the company's patented Carisome™ platform

— a proprietary, blood-based testing technology for diagnosis, prognosis, and

theranosis of cancer and other complex diseases. Through the precise and

personalized information provided by technologies like Caris Target Now and

Carisome, the company believes that the quality of healthcare can be

dramatically improved, while also significantly reducing costs. Headquartered in

the

Dallas

metroplex, Caris Life Sciences offers services throughout

the United

States

,

Europe

, and other international markets. To learn more, please visit

www.carislifesciences.com or www.caristargetnow.com.

[1] About the NCCN Drugs & Biologics Compendium (NCCN Compendium™).

Fort Washington, PA

: National Comprehensive Cancer Network; 2012. Available

at: http://www.nccn.org/professionals/drug_compendium/content/about.asp.

Accessed

May 2, 2012

.